Longboard pharmaceuticals to host investor & analyst event in new york on october 11, 2023

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an investor & analyst event focused on the developmental and epileptic encephalopathy (dee) landscape and lp352, a first-in-class 5-ht2c receptor superagonist in development for the potential treatment of seizures associated with dees. the event will fea.
LBPH Ratings Summary
LBPH Quant Ranking